NEU²

new drugs
against
neurological diseases

 
 

Projects

FKZ* Project Topics Category Participants Start Duration
[months]
Status
0315611

Discovery of small molecule inhibitors of Serine Racemase for potential use in neuroprotection

discovery Evotec AG 2009 36 stopped
16GW0001

Recombinant generation and demonstration of proof of principle of a bispecific Cd20xCD95 antibody construct for the therapy of MS

development Baliopharm GmbH,
University of Tübingen
2013 24 active
0315610

NEU² Program Management

development,
discovery
Bionamics GmbH 2009 43 finished
0315614

Development and validation of a test system for the discovery of new active substances for the treatment of autoimmune diseases

discovery European ScreeningPort GmbH,
Merck KGaA,
UKE/inims
2010 9 finished
0315617

Development of oral therapeutic agents for the treatment of multiple sclerosis (MS)

discovery European ScreeningPort GmbH,
Merck KGaA,
UKE/inims
2010 47 stopped
0315619

Histamine 3 Receptor Antagonists for the Treatment of Fatigue Associated with Multiple Sclerosis

early development Evotec AG,
UKE/inims
2010 24 stopped
0315615

New medicines for the protection of neurons at the first signs of multiple sclerosis (MS)

discovery Evotec AG,
Merck KGaA
2010 41 active
0315620

Treating relapsing-remitting multiple sclerosis (RR-MS) with a human monoclonal antibody (BT061) against CD4

early development Biotest AG,
UKE/inims
2010 40 paused
0315613

MR imaging and clinical trial platform for Multiple Sclerosis drug development

development UKE/inims 2010 66 active
0315612

MS biomarker and platform labs for MS drug discovery and development

development,
discovery
European ScreeningPort GmbH,
UKE/inims
2011 31 finished
0316160

Non-hematopoietic variant of erythropoietin (EPO) for the treatment of chronic progressive MS

development Epomedics GmbH 2012 36 active
16GW0002

Co-development of T-Track® MS, a diagnostic test for monitoring multiple sclerosis

development Lophius Biosciences GmbH 2013 20 active
16GW0064

NEU² Program Management

development,
discovery
Evotec International GmbH 2014 45 active
161A130

NEUCONN – connectivity platform. Novel approaches to analyze the function of neuronal networks in MS

discovery UKE 2012 36 active
161A117

RESCON – escalation therapy study with patients suffering from cortison refractory opticus neuritis

discovery UKE/inims 2012 38 active
16GW0103K

Identification of µRNA and metabolite patterns as biomarkers for the diagnosis treatment response in MS

development Fraunhofer IME Screening Port,
Metabolomic Discoveries GmbH
2014 36 active
16GW0096

Identification of anti-inflammatory compounds inducing IL-27/IL35

discovery Deutsches Rheuma-Forschungszentrum (DRFZ),
Evotec AG
2014 36 active

* Project funding reference number